Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matched analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matched analysis

Published:2021-03 Issue:4 Volume:51 Page:472-481
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Tomonari Tetsu¹^ORCID,Sato Yasushi²^ORCID,Tani Joji³,Hirose Akira⁴,Ogawa Chikara⁵,Morishita Akihiro³,Tanaka Hironori¹,Tanaka Takahiro¹,Taniguchi Tatsuya¹,Okamoto Koichi¹,Sogabe Masahiro¹,Miyamoto Hiroshi¹,Muguruma Naoki¹,Uchida Kazushige⁴,Masaki Tsutomu³,Takayama Tetsuji¹

Affiliation:

1. Department of Gastroenterology and Oncology Institute of Biomedical Sciences Tokushima University Graduate School of Medicine Tokushima Tokushima Japan

2. Department of Community Medicine for Gastroenterology and Oncology Institute of Biomedical Sciences Tokushima University Graduate School of Medicine Tokushima Tokushima Japan

3. Department of Gastroenterology and Neurology Kagawa University Graduate School of Medicine Miki‐cho Kagawa Japan

4. Department of Gastroenterology and Hepatology Kochi University Graduate School of Medicine Kochi Kochi Japan

5. Department of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Kagawa Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13597

Reference31 articles.

1. Cancer statistics, 2018

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

4. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A category: A multicenter study;Hepatology Research;2024-07-02

2. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study;European Journal of Gastroenterology & Hepatology;2024-01

3. Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis;JGH Open;2023-12

4. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments;Digestive and Liver Disease;2023-12

5. Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma;Cancers;2023-10-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3